Citi raised the firm’s price target on ProQR Therapeutics to $2 from $1.80 and keeps a Neutral rating on the shares. The analyst updated the company’s model to reflect the reported Q4 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRQR:
